Sleep disturbances, psychiatric disorders, and psychotropic drugs

Dialogues in Clinical Neuroscience

Volumn 7, Issue 4, 2005, Pages 323-334

  Staner, Luc ^a  

^a FORENAP   (France)

Author keywords

Neurotransmitter; Non rapid eye movement sleep; Polysomnography; Psychiatric disorder; Psychotropic drug; Rapid eye movement sleep; Sleep disturbance; Sleepwake mechanism

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ADENOSINE RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARECOLINE; BENZODIAZEPINE DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NEUROTRANSMITTER; NICOTINE; OREXIN A; OREXIN B; PHYSOSTIGMINE; PSYCHOTROPIC AGENT; TIANEPTINE; TRAZODONE; TRIMIPRAMINE; ZALEPLON; ZOLPIDEM;

BRADYCARDIA; BRAIN FUNCTION; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL PATIENT; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; NONREM SLEEP; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; REM SLEEP; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; MODELS, NEUROLOGICAL; PSYCHOTROPIC DRUGS; SLEEP DISORDERS; SLEEP STAGES;

EID: 30944458274     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry. 1979;136:1257-1262.
2. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225-232.
3. Ohayon M. Epidemiological study on insomnia in the general population. Sleep. 1996;19(suppl):S7-S15.
4. Balter MB, Bauer ML. Patterns of prescribing and use of hypnotic drugs in the United States. In: Clift AD, ed. Sleep Disturbances and Hypnotic Drug Dependence. New York, NY: Excerpta Medica; 1975.
5. National Center for Health Statistics. Selected Symptoms of Psychological Distress. US Public Health Service Publication 1000, Series 11, Number 37. Washington DC: US Department of Health, Education and Welfare; 1970.
6. Steriade M. Arousal: revisiting the reticular activating system. Science. 1996;272:225-226.
7. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci. 2002;3:591-605.
8. Lesch DR, Spire JP. Clinical electroencephalography. In: Thorpy MJ, ed. Handbook of Sleep Disorders. New York, NY: Marcel Dekker; 1990:1-31.
9. Dijk DJ, Czeisler CA. Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett. 1994;166:63-68.
10. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci. 1993;13:1065-1079.
11. Saper CB, Sherin JE, Elmquist JK. Role of the ventrolateral preoptic area in sleep induction. In, Hayaishi O, Inoue S, eds. Sleep and Sleep Disorders: From Molecule to Behaviour. New York, NY: Academic Press; 1997.
12. Staner L, Luthringer R, Macher JP. Développement de molécules actives dans l'insomnie: actualités et aspects methodologiques. Rev Neurol (Paris). 2003;159(11 suppl):6S48-6S55.
13. Jones BE. Arousal systems. Front Biosci. 2003;8:S438-S451.
14. Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states. In: Pace Schott EF, Solms M, Blagrove M, Harnad S, eds. Sleep and Dreaming. Cambridge, UK: Cambridge University Press; 2003:1-50.
15. Lu J, Chou TC, Saper CB. Identification of wake active neurons in the ventral periaqueductal gray (PAG). Presented at: Society of Neuroscience Meeting, 2002 November 2-7, Orlando Fla. Abstract 878.1.
16. 1 antagonist SCH 23390 administration in rats. Neuropsychopharmacology. 1990;3:153-162.
17. Trampus M, Ferri N, Adami M, Ongini E. The dopamine receptor agonists, A 68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol. 1993;235:83-87.
18. 2 receptor stimulation. J Pharmacol Exp Ther. 2003;307:3863-3894.
19. Beuckmann CT, Yanagisawa M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med. 2002;80:329-342.
20. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci. 2002;25:283-313.
21. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretion (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39-40.
22. Peyron C, Farco J, Rogers W, et al. A mutation in a rare case of early onset narcolepsy and a generalised absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991-997.
23. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretins in human narcolepsy. Neuron. 2000;27:469-474.
24. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24:726-731.
25. Chou TC, Bjorkum AA, Gauss SE, et al. Afferents to the ventrolateral preoptic nucleus. J Neurosci. 2002;22:977-990.
26. Basheer R, Strecker RE, Thakkar MM, Mc Carley RW. Adenosine and sleep-wake regulation. Progr Neurobiol. 2004;73:379-396.
27. Chamberlain NL, Arrigoni E, Chou TC, et al. Effects of adenosine on GABAergic synaptic inputs to identified ventrolateral preoptic neurons. Neuroscience. 2003;119:913-918.
28. Morairtry S, Rainnie D, McCarley R, Greene R. Dishinbition of ventrolateral preoptic area sleep-active neurons by adenosine: a new mechanism for sleep promotion. Neuroscience. 2004;123:451-457.
29. Thakkar MM, Winston S, McCarley RW. Orexin neurons of the hypothalamus express adenosine receptors. Brain Res. 2002;944:190-194.
30. Chou TC, Scammell TE, Gooley JJ, Gaus SE, Saper CB, Lu J. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. J Neurosci. 2003;23:10691-10702.
31. Deboer T, Overeem S, Visser NA, et al. Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience. 2004;129:727-732.
32. Sack RL, Hughes RJ, Edgar DM, Lewy AJ. Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep. 1997;20:908-915.
33. Mendelson WB. Melatonin microinjection into the medial preoptic area increases sleep in the rat. Life Sci. 2002;71:2067-2070.
34. Dorfman U, Jarvick ME. Comparative stimulant and diuretic actions of caffeine and theobromine in man. Clin Pharmacol Ther. 1970;11:869-872.
35. Lieberman HR, Wurtman RJ, Emde GG, Roberts C, Coviella IL. The effects of low dose of caffeine on human performance and mood. Psychopharmacology. 1987;92:308-312.
36. Ribeiro JA, Sebastiao AM, de Mendonça A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol. 2002;68:377-392.
37. Fredholm BB, Battig K, Holmen J, Nehlig A, Zwartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
38. Hoppenbrowers ML, Bussche GV. Mioflazine, a nucleoside transport inhibitor is it effective as a sleep promoter in humans? In: Wauqier A, Dugovic C, Radulovacki M, et al, eds. Slow Wave Sleep: Pathophysiological and Functional Aspects. New York, NY: Raven Press; 1989:301-309.
39. Radek RJ, Decker MW, Jarvis MF. The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats. Brain Res. 2004;1026:74-83.
40. Taylor D, Ho BT. Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res Commun Chem Pathol Pharmacol. 1978;21:65-75.
41. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1:49-61.
42. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21:1787-1794.
43. Lin JS, Hou Y, Jouvet M. Pontential brain neuronal targets for amphetamine-, methylpenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93:14128-14133.
44. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998;241:95-98.
45. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20:8620-8628.
46. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett. 1991;123:20-24.
47. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil- and amphetamine-induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591:319-326.
48. de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport. 2001;12:3533-3537.
49. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63:637-672.
50. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. TiPS. 2004;25:618-625.
51. 3-receptor antagonist. J Pharmacol Exp Ther. 1998;287:658-666.
52. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci. 2002;22:7695-7711.
53. 3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology. 2003;167:363-372.
54. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding. Cell. 1998;92:573-578.
55. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438:71-75.
56. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6-25.
57. Lin L, Faracao J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-376.
58. Akanmu MA, Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res. 2005;1048:138-145.
59. 3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology. 1996;15:31-35.
60. Lin JS. Brain structure and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev. 2000;4:471-503.
61. Espana RA, Valentino RJ, Berridge CW. Fos immunoreactivity in hypocretin-synthesizing and hypocretin-1 receptor-expressing neurons: effects of diurnal and nocturnal spontaneous waking, stress and hypocretin-1 administration. Neuroscience. 2003;121:201-217.
62. Winsky-Sommerer R, Yamanaka A, Diano S, et al. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci. 2004;24:11439-11448.
63. Schneider-Helmert D. Twenty-four hour sleep-wake function and personality pattern in chronic insomniacs and healthy controls. Sleep. 1987;10:452-462.
64. Stepanski E, Zorick F, Roehrs T, Young D, Roth T. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep. 1988;11:54-60.
65. Regenstein QH, Dambrosia J, Hallett M, Murawski B, Paine M. Daytime alertness in patients with primary insomnia. Am J Psychiatry. 1993;150:1529-1534.
66. Staner L, Cornette F, Maurice D, et al. Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia. J Sleep Res. 2003;12:319-330.
67. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocr Metab. 2001;86:3787-3794.
68. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med. 1998;60:610-615.
69. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005;46:787-798.
70. Prosise GL, Bonnet MH, Berry RB, Dickel MJ. Effects of abstinence from smoking on sleep and daytime sleepiness. Chest. 1994;105:1136-1141.
71. Wetter DW, Fiore MC, Baker TB, Young TB. Tobacco withdrawal and nicotine replacement influence objective measures of sleep. J Consult Clin Psychology. 1995;63:658-667.
72. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counselling. JAMA. 1995;274:1347-1352.
73. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety. 1998;18:297-308.
74. Gourlay SG, Forbes A, Marriner T, McNeil JJ. Predictors of adverse experiences during transdermal nicotine therapy. Drug Safety. 1999;20:545-555.
75. Salin-Pascual RJ, Moro-Lopez ML, Gonzalez-Sanchez H, Blanco-Centurion C. Changes in sleep after acute and repeated administration of nicotine in the rat. Psychopharmacology. 1999;145:133-138.
76. 2-containing nicotinic receptors contribute to the organization of sleep and regulate putative microarousals in mice. J Neurosci. 2004;24:5711-5718.
77. Gillin JC, Lardon M, Ruiz C, Golshan S, Salinpascual R. Dose-dependent effects of transdermal nicotine on early morning awakening and rapid eye movement sleep time in non-smoking normal volunteers. J Clin Psychopharmacol. 1994;14:264-267.
78. Davila DG, Hurt RD, Offord KP, Harris CD, Shepard JW. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Resp Critic Care Med. 1994;150:469-471.
79. Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G. Sleep effects of a 24-hour versus a 16-hour nicotine patch: a polysomnographic study during smoking cessation. Sleep Med. 2005. In press.
80. Brower KJ. Alcohol's effects on sleep in alcoholics. Alcohol Res Health. 2001;25:110-125.
81. Little HJ. The contribution of electrophysiology to knowledge of acute and chronic effects of ethanol. Pharmacol Ther. 1999;84:333-353.
82. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-Methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment and vulnerability. Pharmacol Ther. 2003;99:79-94.
83. Grant KA, Lovinger DM. Cellular and behavioural neurobiology of alcohol: receptor-mediated neuronal processes. Clin Neurosci. 1995;3:155-164.
84. Woodward JJ. Ionotropic glutamate receptors as sites of action for ethanol in the brain. Neurochem Int. 1999;35:107-113.
85. Holter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol. 1996;314:R1-R2.
86. Holter SM, Danysz W, Spanagel R. Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Exp Ther. 2000;292:545-552.
87. Mason BJ. Treatment of alcohol dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62:42-48.
88. Bolo N, Nedelec JF, Muzet M, et al. Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res. 1998;82:115-127
89. Schneider U, Wohlfart K, Schulze-Bonhage A, et al. Lack of psychotomimetic or impairing effect on psychomotor performance of acamprosate. Pharmacopsychiatry. 1998;31:110-113.
90. Boeijinga PH, Parot P, Soufflet L, et al. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology. 2004;50:71-77.
91. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300:2-8.
92. Steriade M. Corticothalamic resonance, states of vigilance and mentation. Neuroscience. 2000;101:243-276.
93. A receptor subtype. Proc Natl Acad Sci U S A. 2001;98:6646-6649.
94. A receptor subtype. Eur J Neurosci. 2003;17:2226-2230.
95. A receptor subtype and state specificity. Proc Natl Acad Sci U S A. 2004;101:3674-3679.
96. A receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep. 1999;22:33-42.
97. Gottesman C. GABA mechanisms and sleep. Neuroscience. 2002;111:231-239.
98. Mendelson WB, Gillin JC, Wyatt RD. Human Sleep and its Disorders. New York, NY: Plenum; 1977.
99. Reynolds CF III, Kupfer DJ. Sleep research in affective illness: state of the art circa 1987. Sleep. 1987;10:199-215.
100. Buysse DJ, Kupfer DJ. Diagnostic and research applications of electroencephalographic sleep studies in depression: conceptual and methodological issues. J Nerv Ment Dis. 1990;178:405-414.
101. Insel TR, Gillin JC, Moore A, et al. The sleep of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1982;39:1372-1377.
102. Uhde TW, Roy-Byrne P, Gillin JC, et al. The sleep of patients with panic disorder. A preliminary report. Psychiatry Res. 1984;12:251-259.
103. Rosa RR, Bonnet MH, Kramer M. The relationship of sleep and anxiety in anxious subjects. Biol Psychol. 1983;16:119-126.
104. Reynolds CF 3rd, Soloff PH, Kupfer DJ, et al. Depression in borderline patients: a prospective EEG sleep study. Psychiatry Res. 1985;14:1-15
105. Katz JL, Kuperberg A, Pollack CP, et al. Is there a relationship between eating disorder and affective disorder? New evidence from sleep recordings. Am J Psychiatry. 1984;141:753-759.
106. Moeller FG, Gillin JC, Irwin M, et al. A comparison of sleep EEGs in patients with primary major depression and major depression secondary to alcoholism. Effect Disord. 1993;27:39-42.
107. McCarley RW. REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry. 1982;139:565-570.
108. Staner L, Luthringer R, Macher JP. Effects of antidepressant drugs on sleep EEG in patients with major depression. Mechanisms and therapeutic implications. CNS Drugs. 1999;11:49-60.
109. Nofzinger EA, Buysse DJ, Germain A, et al. Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry. 2004;61:695-672.
110. Riemann D, Berger M, Voderholzer U. Sleep and depression - results from psychobiological studies: an overview. Biol Psychol. 2001;57:67-103.
111. Gillin JC, Sitaram N, Wehr T, et al. Sleep and affective illness. In, Post RM, Ballenger JC, eds. Neurobiology of Mood Disorders. Baltimore, Md: Williams &z Wilkins; 1984:157-188.
112. Moore P, Gillin JC, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry. 1998;55:534-539.
113. Evans L, Golshan S, Kelsoe J, et al. Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion. Neuropsychopharmacology. 2002;27:1016-1026.
114. Landolt HP, Kelsoe JR, Rapaport MH, Gillin JC. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res. 2003;12:13-18.
115. Haynes PL, McQuaid JR, Kelsoe J, et al. Affective state and EEG sleep profile in response to rapid tryptophan depletion in recently recovered non-medicated depressed individuals. J Affect Disord. 2004;83:253-262.
116. Bhatti T, Gillin JC, Seifritz E, et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and sleep. Biol Psychiatry. 1998;43:52-59.
117. Voderholzer U, Hornyak M, Thiel B, et al. Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology. 1998;18:112-124.